Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhlis Cem Ar

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|May 13, 2014
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylateAhmet Emre Eskazan, Mesut Ayer, Bulent Kantarcioglu, et al.
African Health Sciences|March 13, 2023
Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literatureAyse Cirakoglu, Rahiye Dilhan Kuru, Sukriye Yilmaz, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 23, 2025
The Skin Tells the Story: Early Signs of Inborn Errors of ImmunityZeynep Meric, Betul Kosa, Betul Gemici Karaaslan, et al.
Hematology (Amsterdam, Netherlands)|October 10, 2017
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literatureSeniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|January 26, 2023
Acquired Hemophilia A In Adults: A Multicenter Study from TurkeyEren Arslan Davulcu, Zühal Demirci, Umut Yılmaz, et al.
Journal of Clinical Pathology|January 27, 2016
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemiaEda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, et al.
Leukemia & Lymphoma|August 22, 2015
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysisErman Öztürk, Murat Özbalak, Selin Berk, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 3, 2022
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center ExperienceMurat Özbalak, Metban Güzel Mastanzade, Özden Özlük, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|February 21, 2020
Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review StudyYahya Büyükaşık, Rıdvan Ali, Mehmet Turgut, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 30, 2017
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and GlivecAhmet Emre Eskazan, Sevil Sadri, Dilek Keskin, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|May 13, 2014
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylateAhmet Emre Eskazan, Mesut Ayer, Bulent Kantarcioglu, et al.
African Health Sciences|March 13, 2023
Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literatureAyse Cirakoglu, Rahiye Dilhan Kuru, Sukriye Yilmaz, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 23, 2025
The Skin Tells the Story: Early Signs of Inborn Errors of ImmunityZeynep Meric, Betul Kosa, Betul Gemici Karaaslan, et al.
Hematology (Amsterdam, Netherlands)|October 10, 2017
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literatureSeniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|January 26, 2023
Acquired Hemophilia A In Adults: A Multicenter Study from TurkeyEren Arslan Davulcu, Zühal Demirci, Umut Yılmaz, et al.
Journal of Clinical Pathology|January 27, 2016
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemiaEda Tanrikulu Simsek, Ahmet Emre Eskazan, Mahir Cengiz, et al.
Leukemia & Lymphoma|August 22, 2015
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysisErman Öztürk, Murat Özbalak, Selin Berk, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 3, 2022
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center ExperienceMurat Özbalak, Metban Güzel Mastanzade, Özden Özlük, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|February 21, 2020
Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review StudyYahya Büyükaşık, Rıdvan Ali, Mehmet Turgut, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 30, 2017
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and GlivecAhmet Emre Eskazan, Sevil Sadri, Dilek Keskin, et al.
Pageof 11